Background
cardiovascular and renal benefits, T2D, type 2 diabetes, LVH
LVH, TYPE 2 DIABETES, SUDDEN DEATH, LEFT VENTRICULAR HYPERTROPHY
Sodium-glucose transport protein 2 inhibitors (SGLT2i) have shown marked cardiovascular and renal benefits in patients with type 2 diabetes (T2D) [There have been many suggested mechanisms to explain the cardiovascular benefits associated with SGLT2i [Left ventricular hypertrophy (LVH) is an established predictor of poor cardiovascular outcomes, while increases in LVMi have been independently associated with all-cause mortality and sudden death [